Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib

Authors

Institutions

Publication Details

Journal
JAMA Dermatology
Published
2025-02-26
DOI
https://doi.org/10.1001/jamadermatol.2024.6574
Citations
2
Primary Topic
Neurofibromatosis and Schwannoma Cases
Type
article
Field-Weighted Citation Impact
2.78
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib

Andrea M. Gross, Olivia H. Reid, Bruce R. Korf, Ashley Cannon et al.
2 citations
JAMA Dermatology
Neurofibromatosis and Schwannoma Cases
2.78
article

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib

Andrea M. Gross, Olivia H. Reid, Bruce R. Korf, Ashley Cannon, Lauren Baldwin, Cecilia Tibery, Mina Lobbous, Seth M. Steinberg, Dominique C. Pichard, Eva Dombi, Joanne Derdak, Pamela L. Wolters, Brigitte C. Widemann, Hyoyoung Choo‐Wosoba
article en
2 citations

Abstract

No abstract available for this paper.
JAMA DermatologyVol. 161(5)
Leidos (United States) (US), National Institutes of Health (US), University of Alabama at Birmingham (US), National Institute of Arthritis and Musculoskeletal and Skin Diseases (US), Frederick National Laboratory for Cancer Research (US), National Cancer Institute (US), National Center for Advancing Translational Sciences (US), Center for Cancer Research (US), Leidos Biomedical Research Inc. (United States)
Openalex Percentile: Top 12%
Neurofibromatosis and Schwannoma Cases
2.78
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1 With MEK Inhibitor Selumetinib — Andrea M. Gross, Olivia H. Reid, et al. · JAMA Dermatology (2025) | TGRS Research Map | TGRS